Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer
{{output}}
HER2 mutations define a distinct molecular subset of non-small cell lung cancer (NSCLC) associated with poor outcomes and limited benefit from conventional systemic therapies. Zongertinib is a next-generation, HER2-selective irreversible tyrosine kinase inhibi... ...
